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Abstract
Background: The amygdala-kindled rat is a model for human temporal lobe epilepsy and activity-dependent
synaptic plasticity. Hippocampal RNA isolated from amygdala-kindled rats at different kindling stages was analyzed
to identify kindling-induced genes. Furthermore, effects of the anti-epileptic drug levetiracetam on kindling-
induced gene expression were examined.
Results: Cyclooxygenase-2 (Cox-2), Protocadherin-8 (Pcdh8) and TGF-beta-inducible early response gene-1 (TIEG1)
were identified and verified as differentially expressed transcripts in the hippocampus of kindled rats by in situ
hybridization and quantitative RT-PCR. In addition, we identified a panel of 16 additional transcripts which included
Arc, Egr3/Pilot, Homer1a, Ania-3, MMP9, Narp, c-fos, NGF, BDNF, NT-3, Synaptopodin, Pim1 kinase, TNF-a, RGS2,
Egr2/krox-20 and b-A activin that were differentially expressed in the hippocampus of amygdala-kindled rats. The
list consists of many synaptic plasticity-related immediate early genes (IEGs) as well as some late response genes
encoding transcription factors, neurotrophic factors and proteins that are known to regulate synaptic remodelling.
In the hippocampus, induction of IEG expression was dependent on the afterdischarge (AD) duration.
Levetiracetam, 40 mg/kg, suppressed the development of kindling measured as severity of seizures and AD
duration. In addition, single animal profiling also showed that levetiracetam attenuated the observed kindling-
induced IEG expression; an effect that paralleled the anti-epileptic effect of the drug on AD duration.
Conclusions: The present study provides mRNA expression data that suggest that levetiracetam attenuates
expression of genes known to regulate synaptic remodelling. In the kindled rat, levetiracetam does so by
shortening the AD duration thereby reducing the seizure-induced changes in mRNA expression in the
hippocampus.
Background
Human temporal lobe epilepsy (TLE) is a neurological
brain disorder affecting approximately 0.5% of the popu-
lation [1]. There exist monogenetic forms of TLE. How-
ever, most forms are either symptomatic or idiopathic
[2,3]. The symptomatic forms of human temporal lobe
epilepsy results from various kinds of brain injury, e.g.
stroke, ischemia, head trauma, infections, febrile seizures
and brain surgery [4]. In these cases the epileptic process
generally comprises three phases i) the initial precipitat-
ing insult ii) the latent epileptogenic phase and iii) epi-
lepsy, i.e. recurrent complex partial seizures with
secondary generalisation. Most of the current drug thera-
pies only relieve the convulsive state whereas they have
no clinically documented effect on the development of
the epileptic condition [5]. TLE is also the most common
form of treatment resistant epilepsy in adult epileptic
patients. Here, the seizure activity typically originates in
the hippocampal formation, which also exhibits neuro-
pathological features such as hippocampal sclerosis asso-
ciated with the TLE [6]. Ideally, animal models of
epilepsies should share the characteristics of the acquired
human disease, i.e. a) exhibit spontaneous seizures fol-
lowing the latent period, b) have a resembling pathophy-
siology which should include hippocampal sclerosis c)
exhibit synaptic and neuronal reorganisation which
should include mossy fiber sprouting and neurogenesis
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The amygdala-kindling model initially characterized by
Goddard and colleagues [8] comprises many if not all of
these features of human TLE [5,8-10].
The newer anti-epileptic drug levetiracetam has shown
anti-epileptic efficacy in the amygdala-kindled rat
[11-13]. In addition, it reduces the frequency of sponta-
neous seizures after pilocarpine-induced status epilepti-
cus [14]. Levetiracetam has proven efficacious as
adjunctive therapy in patients with partial seizures [15]
and in treating patients with idiopathic generalized epi-
lepsy where therapy with other anti-epileptic drugs has
failed [16]. It also reduces the frequency of interictal
epileptiform discharges in patients with partial seizures
[17]. In contrast, levetiracetam is devoid of anti-convul-
sant activity in maximal electroshock and pentylenete-
trazole (PTZ) seizure tests [18,19]. Levetiracetam
binding is highly enriched in cortical, hippocampal and
cerebellar regions [20] and it can selectively bind to
synaptic fractions purified from these regions [21]. The
binding site for levetiracetam has been identified as the
synaptic vesicle protein 2A (SV2A) [22]. It is expressed
in synaptic vesicles [23] and although the exact function
of SV2A has not yet been resolved the functional signifi-
cance of SV2A is evident from studies showing that
homozygous KO mice suffer from severe seizures and
die postnatally [24,25]. Several studies have reported on
late response gene expression profiling in rats with sta-
tus epilepticus-induced spontaneous seizures [26-28].
However, based on the involvement of the hippocampal
formation in human TLE we hypothesize that additional
insights into the basic mechanisms and effects of levetir-
acetam treatment of human TLE might be achieved by
also studying early gene expression changes in hippo-
campal tissue isolated from the amygdala-kindling rat
model of human TLE. Thus, in the present study we
aim at the following. Firstly, to identify differential
expressed early genes (within 3 hours after the last sei-
zure) by analysing gene expression changes in the hip-
pocampus from amygdala-kindled rat as a function of
kindling and secondly, examine the effect of levetirace-
tam on kindling-induced gene expression.
Methods
Animals
Male Wistar rats (Møllegård Breeding Center, Denmark)
weighing approximately 300 g at the time of surgery were
housed in plastic cages (35 × 30 × 12 cm) in groups of 2.
Room temperature (21 ± 2°C), relative humidity (55 ± 5%),
and air exchange (16 times per hour) were automatically
controlled. The animals had free access to conventional
laboratory chow and water and they were subjected to a
normal light:dark cycle (light 06:00-18:00). All animal pro-
cedures were carried out in compliance with the EC
Directive 86/609/EEC and with the Danish law regulating
experiments on animals.
Amygdala-kindling and levetiracetam treatment
Animals were anaesthetized with 2 ml/kg subcutaneously
(s.c.) administered Hypnorm/Dormicum/H2O (1:1:2) v/v.
Bipolar electrodes were stereotactically implanted into the
basolateral amygdaloid nuclei of the right amygdala
according to Paxinos’ coordinates (DV -8.4, L -4.8 and AP
-2.8 from bregma). One week after surgery afterdischarge
(AD) threshold currents were determined by gradually
increasing the stimulating current by 25 μAf r o m7 5μA
until an AD was evoked. Here, an AD was defined as a
spike train with duration of at least 3 seconds. Subse-
quently, the rats were electrically stimulated every second
weekday (Mondays, Wednesdays and Fridays; Weekends
off) at the pre-determined AD threshold current. AD
duration was measured by EEG and seizure severity (SS)
was scored according to Racine’s 5-stage behavioural scale
for convulsive responses [29]. Seizure duration was scored
as the duration of a convulsive seizure; however, this was
only assessed for stage 5 animals. The animals were
divided into kindled animals and non-kindled control ani-
mals. All animals had electrodes implanted in the basolat-
eral amygdala. Prior to the experiment, the kindled
animals were paired, with one vehicle treated and one
levetiracetam treated rat in each kindling pair. The kindled
animal pairs were stimulated 1 hour after either i.p. injec-
tion of vehicle or 40 mg/kg levetiracetam, respectively.
During the experiment, animal pairs were sacrificed at dif-
ferent behavioural stages thus giving a total of 5 experi-
mental groups (see Table 1): Group 1 consisted of
operated but non-kindled rats and was sacrificed at the
start of the experiment (n = 5); group 2, consisted of ani-
mals with 1-3 consecutive stage 3 seizures (n = 7); group
3, consisted of animals with one or two stage 5 seizures
(n = 5); group 4, was fully kindled animals with at least 10
consecutive stage 5 seizures (n = 5) and group 5, was oper-
ated but not kindled sacrificed at the end of the experi-
ments (n = 6). Three hours after the last stimulation
animals were decapitated and blood from the levetirace-
tam treated animals was collected and stored at -80°C.
Gene expression assays
Following decapitation, hippocampi were quickly dis-
sected and total RNA from the entire hippocampus
(dorsal and ventral regions) was separately purified
using the RNeasy Mini Kit (Qiagen, Hilden, Germany).
Prior to the isolation procedure tissue was disrupted by
a pestle fitting into an Eppendorf tube and lysed in lysis
buffer supplied with the kit. The RNA was on column
DNase-treated for 30 minutes with Rnase-free DNase
Set (Qiagen) and finally eluted in 2 times 30 μlo f
DEPC-treated H2O.
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Group Treatment Animal
number
Seizure
Severity
Afterdischarge
duration (s)
Seizure
duration (s)
Total no. of
stimulations
[LEV]plasma
mg/L
Amplitude
(μA)
CS1 - - - - - -
CS2 - - - - - -
Control - CS3 - - - - - -
start CS4 - - - - - -
CS5 - - - - - -
3V1 3 68 n.d. 6 - 150
3V2 3 69 n.d. 6 - 100
3V3 3 8 n.d. 6 - 350
Vehicle 3V4 3 41 n.d. 18 - 150
3V5 3 71 n.d. 20 - 150
3V6 3 7 n.d. 22 - 250
1 3V7 3 75 n.d. 22 - 150
3L1 0 16 n.d. 6 19.7 450
3L2 3 12 n.d. 6 33.2 225
Levetiracetam 3L3 0 14 n.d. 6 31 325
40 mg/kg 3L4 1 12 n.d. 18 24 350
3L5 0 10 n.d. 20 23.1 200
3L6 1 11 n.d. 22 20.1 300
3L7 5 42 20 22 23.6 375
5V1 5 46 41 23 - 325
5V2 5 127 48 31 - 175
Vehicle 5V3 5 105 44 36 - 225
5V4 5 23 18 42 - 400
2 5V5 5 122 96 40 - 300
5L1 1 37 n.d. 23 23.3 375
Levetiracetam 5L2 0 83 n.d. 31 24.3 125
40 mg/kg 5L3 5 18 10 36 27 325
5L4 3 19 n.d. 42 n.d. 275
5L5 3 71 n.d. 40 18.9 250
FV1 5 95 41 14 - 250
FV2 5 98 42 14 - 375
Vehicle FV3 5 120 55 19 - 200
FV4 5 132 43 22 - 150
3 FV5 5 78 59 25 - 350
FL1 5 13 12 14 19.6 275
Levetiracetam FL2 1 16 n.d. 14 27.5 200
40 mg/kg FL3 5 12 14 19 39.7 500
FL4 1 9 n.d. 22 22.6 150
FL5 5 69 31 25 18.5 100
CE1 - - - - - -
CE2 - - - - - -
Control - CE3 - - - - - -
end CE4 - - - - - -
CE5 - - - - - -
CE6 - - - - - -
n.d., not determined
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For the DDRT-PCR analysis we used pooled total RNA
from the contralateral hippocampus of vehicle treated
animals in the 3 kindling groups and the 2 control
groups: control start (n = 5), stage 3 vehicle treated
(n = 7), stage 5 vehicle treated (n = 5), fully kindled
vehicle treated (n = 5) & control end (n = 6). The
DDRT-PCR analysis was performed using 288 different
primer combinations as described previously [30].
Quantitative RT-PCR
To further profile the kindling-induced alterations in
gene expression quantitative RT-PCR of pooled total
RNA was performed. Gene-specific primers were
designed according to the following guidelines (Addi-
tional file 1, Table S1): an amplicon size of 50-150 base-
pairs, GC content within the 20-80% range, no runs of
identical nucleotides and a Tm between 58-60°C. We
used the Taqman® Reverse Transcription reagents
(Applied Biosystems, Foster City, CA) to perform first
strand synthesis on 1 μg total RNA according to the
manufacturer’s prescriptions with 2.5 μM random hex-
amers by incubating a 100 μl reaction 10 minutes at 25°
C, 30 minutes at 48°C and finally 5 minutes at 95°C.
After synthesis the cDNA was diluted twice with Rnase-
free H2Oa n d3μl was used in a 20 μl quantitative RT-
PCR reaction containing 1 × SYBR Green® Mix (Applied
Biosystems) and 7.5 pmol of each primer. The samples
were analyzed on the DNA Engine Opticon (MJ
Research, Waltham, MA) with cycle conditions as fol-
lows: 2 minutes at 50°C; 10 minutes at 95°C; 40 cycles
of 15 seconds at 95°C and 1 minute at 60°C. Quantita-
tive PCR measurements was either analyzed by applying
the 2
-ΔΔCT or the Pfaffl method [31-34]. In short, the
relative expression level of each cDNA was calculated
by normalizing to the expression levels of b-actin or
cyclophilin A (PPIA) in the sample, and set relative to
the mean normalized expression levels of the control
samples. GAPDH was used as a negative control. Each
quantitative RT-PCR experiment has been done twice of
which only one representative experiment is shown. Tri-
plicate qPCR data is presented as mean ± SEM. It is
indicated in the figure legends when quantitative analy-
sis of RNA from individual animals rather than pooled
RNA has been performed.
In situ hybridization
Radioactive in situ hybridization with
33P-riboprobes
was done on 12 μm coronal cryosections from amyg-
dala-kindled and control rat brain. The brains were cut
in a cryostat and transferred onto Superfrost Plus slides.
Subsequently, cryosections were fixed in 4% PFA for 5
minutes, washed in PBS for 2 minutes, incubated for 2
minutes in acetic anhydride/triethanolamine, washed in
PBS for 2 minutes and dehydrated in increasing concen-
trations of EtOH (from 30%-99%).
The differentially regulated DDRT-PCR bands were
amplified using the downstream T7-promoter harbouring
poly-T primer and a designed gene-specific upstream pri-
mer with a T3-promoter overhang. The riboprobes were
in vitro transcribed from either the T7-promoter (anti-
sense) or T3-promoter (sense) in the PCR-amplified frag-
ments using the Maxiscript in vitro transcription kit
(Ambion, Austin, TX). Recovery of the in vitro tran-
scribed fragments was performed on NucAway Spin col-
umns (Ambion) according to the manufacturer’s
instructions. Each probe was denatured for 3 min at 80°C
and after cooling 1-2 μl probe was transferred to 150 μl
hybridization buffer containing 50% 2 × HYBE solution
(SIGMA), 50% deionised formamide, 10% dextrane sul-
phate and 1 mg/ml tRNA. The hybridization mix was
transferred to the processed cryosections, covered with a
coverslip and incubated ON at 60°C. After ON hybridiza-
tion coverslips were removed in 1× SSC/50% formamide,
washed in 2 × 30 minutes at 42°C in 1 × SSC/50% forma-
mide, RNase-treated for 30 minutes at 37°C, dehydrated
in increasing concentrations of EtOH (30%-99%) each
containing 300 mM ammonium acetate, washed twice in
99% EtOH and finally exposed for 3-4 weeks on Biomax
film (Kodak).
Plasma concentrations of levetiracetam
Rats were decapitated 3 hours after the last i.p. injection
of levetiracetam and full blood was collected in sodium-
heparin tubes and centrifuged (5000 rpm) for 10 minutes.
Subsequently, plasma was collected and frozen at -80°C
until analysis. By using validated HPLC methods, solvent
extraction and UV detection the concentration of levetir-
acetam in plasma was determined in duplicate and
results were only accepted if the plasma levels deter-
mined were within 10% of each other. In the case of ani-
mal 5L4 the levetiracetam plasma concentration could
not be determined. Hence, RNA from rat 5L4 and its
levetiracetam paired animal 5V4 were not included in the
subsequent qPCR analysis.
Results
Kindling procedure
One week after implantation of the stimulation electro-
des the kindled rats were divided in two halves (Table 1).
Half of the animals received vehicle and the other half
received 40 mg/kg levetiracetam i.p. 1 hour prior to the
kindling stimulation. In addition, the kindled animals
were also grouped in kindling pairs, with one vehicle (V)
treated rat and one levetiracetam (L) treated rat in each
kindling pair. The initial pairing of animals secured that
each levetiracetam treated rat was paired with a vehicle
treated control rat, and that the number of stimulations
received by the levetiracetam treated rat was matched to
that of its pair-housed vehicle treated control rat. A
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rats in the “Stage 3” group actually will reach Stage 3 sei-
zures, not all levetiracetam treated in the “Stage 5” will
reach Stage 5 seizures and so forth. Prior to the experi-
ments, 5 electrode implanted non-kindled control ani-
mals (CS1-5; see Table 1) were sacrificed. During the
experiment kindling pairs were sacrificed at 3 different
kindling stages thus giving 3 different kindling groups. In
the stage 3 group, a total of 7 kindling pairs (3V1-7 and
3L1-7; see Table 1) were selected when the vehicle ani-
mals reached stage 3 seizures; in that group, 3 kindling
pairs (3V1-3 and 3L1-3) were selected and sacrificed
after 6 stimulations and another 4 kindling pairs (3V4-7
and 3L4-7) were sacrificed after 18-22 stimuli. In the
stage 5 group, 5 kindling pairs (5V1-5 and 5L1-5) were
sacrificed when the vehicle animals reached the first or
t h es e c o n ds t a g e5s e i z u r e .I nt h ef u l l yk i n d l e dg r o u p ,
consisting of 5 kindling pairs (FV1-5 and FL1-5), animal
pairs were sacrificed when the vehicle animals reached
the fully kindled stage (10 consecutive stage 5 seizures).
Finally, in order to control for variation in age related
gene expression, six operated but non-kindled animals
(CE1-6) were sacrificed at the end of the kindling
experiment.
Amygdala kindling
The mean number of stimulations needed for a rat to
reach a stage 3 seizure was 8.9 ± 2.2 stimulations (mean
± SEM, n = 17) whereas the mean number of stimula-
tions needed to reach the first stage 5 seizure was 20.4
± 2.3 stimulations (mean ± SEM, n = 10). The mean
AD duration on the last day of kindling for stage 3,
stage 5 and fully kindled rats were 48.4s ± 11.4s, 84.6s ±
21.09s and 104.6s ± 9.6s (mean ± SEM, n = 5-7),
respectively.
Effect of levetiracetam in amygdala-kindled rats
Levetiracetam significantly reduced the seizure severity
(Figure 1A) and AD duration (Figure 1B) when com-
pared to vehicle treated amygdala-kindled rats. Only
2 9 %o ft h ea n i m a l s( 5o f1 7a n i m a l s )t r e a t e dw i t hl e v e -
tiracetam experienced a stage 5 seizure compared to
59% of the vehicle treated animals. No linear correlation
existed between the inability of levetiracetam to attenu-
ate development of stage 5 kindling and the plasma
levels of levetiracetam (see Table 1). The correlation
coefficients for plasma levels versus seizure severity and
AD duration were 0.13 (linear regression, r
2 = 0.1283,
ns) and 0.36 (linear regression, r
2 = 0.017, ns),
respectively.
A two-way ANOVA analysis showed that there was
both a statistically significant kindling effect and a statis-
tically significant levetiracetam effect in amygdala-
kindled rats treated with levetiracetam when measured
on parameters such as seizure severity (Figure 1C) and
AD duration (Figure 1D). On the contrary there was no
interaction between the drug and kindling suggesting
that the effect of levetiracetam has no differential effect
with respect to the different kindling groups. Adminis-
tration of levetiracetam also lowered the seizure dura-
tion (17.4s ± 3.8s) significantly compared to vehicle
treated amygdala-kindled rats (48.7s ± 6.3s, students
t-test; P < 0.005). Four animals receiving levetiracetam
showed no seizures and five animals developed seizures
less severe than stage 3 (see Table 1 for last day stimula-
tion parameters). Additionally, no animal receiving leve-
tiracetam experienced AD durations of more than 90 s
compared to 7 vehicle animals. No behavioural adverse
effects of the drug treatment were observed during the
entire kindling experiment.
Identification of differentially expressed mRNAs in vehicle
treated amygdala-kindled rats
To identify differentially expressed transcripts during
kindling acquisition, total RNA was purified from the
ipsilateral hippocampus of 2 groups of non-kindled and
3 groups of vehicle treated kindled rats 3 hours after
their last seizure activity and subsequently, pooled and
screened for transcriptional differences by the Differen-
tial Display RT-PCR (DDRT-PCR) method [35]. In all 3
kindling stages compared to the non-kindled controls
Cox-2, Pcdh-8 and TIEG1 were identified as differen-
tially expressed transcripts (Figure 2A-C, top inserts).
No change in GAPDH levels were observed (Figure 2D).
Quantitative RT-PCR with primers amplifying Cox-2,
TIEG1 and Pcdh-8 revealed a good correlation between
the ipsi- and contralateral hippocampus in the relative
expression of kindling-induced gene expression (Addi-
tional File 1, Figure S1). This suggests that expression
levels in the contralateral hemisphere are predictive for
the expression levels in the ipsilateral hemisphere at the
analyzed kindling stages (≥ stage 3). On the contrary,
quantitative RT-PCR analysis done on total hippocampal
RNA from individual rats shows that there was no sig-
nificant difference in the expression levels between the
individual kindling stages of Cox-2, Pcdh-8 and TIEG1
(Figure 3A-D) suggesting either that a) the induction of
these genes in the hippocampus are not underlying the
epileptogenic process or b) that the epileptogenic pro-
cess is ongoing at earlier time-points. Localization of the
kindling-induced transcripts of Pcdh8 and TIEG1 was
determined to the dentate gyrus by in situ hybridization
(ISH) on cryosections from stage 3 amygdala kindled
and control rats with
33P labelled riboprobes (Additional
file 1, Figure S2) which fits with previous observations
for Cox-2 [36,37].
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in amygdala-kindled rats
Based on the differential expressed transcripts identified
in the DDRT-PCR analysis and expression changes of
genes related to those transcripts (data not shown) we
examined the literature for genes previously reported as
involved in models of neuronal or synaptic activity
including maximal electroconvulsive shock, kainate
induced seizures, long-term potentiation, long-term
depression, chronic epilepsy models including amygdala-
hippocampal kindling as well as models with sponta-
neous seizure activity after pilocarpine- and PTZ-
induced status epilepticus. We identified 105 genes from
these studies (see Additional file 1, Table S1 for genes
and primer sequences) and then examined the mRNA
expression levels by quantitative PCR of total RNA iso-
lated from the ipsilateral hippocampus of control and
amygdala-kindled rats at different kindling stages (see
Additional file 1, Table S2 for relative mRNA levels).
Nineteen genes including the 3 genes identified by
DDRT-PCR were verified as differentially expressed in
the amygdala-kindled rat relative to non-kindled control
rats (Additional file 1, Table S3 and Table S4). Some
genes that previously have been strongly linked to amyg-
dala-kindling such as NPY [38] only showed nominal
differential expression compared to either of the control
groups and therefore were omitted from further analysis.
Many of the 19 qpcr validated transcripts have pre-
viously been identified as IEGs and fewer genes such as
synaptopodin and beta-A activin as late response genes
(for review see Lanahan, 1998) [39]. The levels of cyclo-
philin A and GAPDH, which were included as controls
showed no differential expression in amygdala-kindled
rats compared to control animals.
Effects of levetiracetam on kindling-induced gene
expression
The effect of the anti-epileptic drug levetiracetam on the
identified kindling-induced genes was determined using
quantitative RT-PCR on total ipsilateral hippocampal
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Figure 1 Anti-epileptic effects of levetiracetam in the amygadala-kindled rat. A. Seizure severity of amygdala-kindled rats on the final day
of stimulation. B. After discharge duration of amygdala-kindled rats on the final day of stimulation. Animals in vehicle group (n = 17) and
levetiracetam group (n = 17) were administred 0.9% NaCl solution or 40 mg/kg levetiracetam, respectively. Data is presented by mean values ±
SEM. Asterisks indicate a significant difference in mean values between vehicle and levetiracetam groups. (p < 0.05, *; p < 0.01, **; Mann-Whitney
test). C. Seizure severity of stage 3 rats (n = 7), stage 5 rats (n = 5) and fully kindled rats (n = 5) on the final day of stimulation. D. After discharge
duration of stage 3 rats (n = 7), stage 5 rats (n = 5) and fully kindled rats (n = 5) on the final day of stimulation. 2-way ANOVA was performed
with respect to kindling effect and levetiracetam effect. The F-statistics and p-values for the kindling effect (black square) and levetiracetam
effect (black circle) in each ANOVA are indicated in the figure.
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Page 6 of 15RNA from control, vehicle and levetiracetam animals
and on total contralateral hippocampal RNA from vehi-
cle and levetiracetam animals (Table 2 and Additional
file 1, Figure S3). The housekeeping gene GAPDH was
included as control and all expression levels were nor-
malized to the b-actin levels. A subset of genes was also
tested on the single animal level and here levetiracetam
when compared to vehicle significantly attenuated the
kindling-induced expression in the hippocampus of
amygdala-kindled rats in all of the analyzed transcripts
(Figure 4). There was no significant difference in the
mRNA levels of the control transcripts GAPDH and the
levetiracetam target SV2A when comparing levetirace-
tam animals to vehicle controls. Also to rule out a gen-
eral detrimental effect of levetiracetam on hippocampal
neurons the mRNA expression levels of a set of consti-
tutively expressed neuronal mRNAs were measured.
There was no observed significant effect of levetiracetam
compared to vehicle on the mRNA levels of neuronal
t r a n s c r i p t ss u c ha sH o m e r - 1 b / c ,C A M K I I ,G l u R 2 ,
Synapsin I and Synaptophysin (Additional file 1, Figure
S4 and Table S3).
Figure 2 Identification and verification of differential expressed Pcdh-8, TIEG1 and COX-2 transcripts in the ipsilateral hippocampus of
amygdala-kindled rats 3 hrs after the last seizure. Quantitative RT-PCR on total RNA from control and amygdala-kindled rats of A. Pcdh-8, B.
COX-2, C. TIEG1 and D. GAPDH. The relative expression level of each cDNA was calculated by the ΔΔ-method, normalized to the expression
levels of b-actin in the sample, and set relative to the mean normalized expression levels of the control samples. GAPDH was used as a control.
Each quantitative RT-PCR experiment has been done twice of which one representative experiment is shown. Triplicate qPCR data is presented
as mean ± SEM. Top inserts A-C, autoradiograms showing the DDRT-PCR bands corresponding to Pcdh-8, COX-2 and TIEG1, respectively. Arrow
indicates the DDRT-PCR analysed bands. The 5 lanes correspond to control start, stage 3, stage 5, fully kindled and control end, respectively.
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kindling-induced IEG expression in both the ipsi- and
contralateral hippocampus was determined. Here, it was
found that the average reduction in kindling-induced
expression by levetiracetam was approximately 65% in
both the ipsi- and the contralateral hippocampus (Table
2). A linear correlation was observed between the per-
centage reductions by levetiracetam in the ipsi- versus
the contra-lateral hippocampus (correlation coefficient
0.93; linear regression, r
2 = 0.8622, P < 0.001). Next, we
wanted to examine the effect of levetiracetam on inter-
individual gene expression. However, when plotted indi-
vidually a large underlying inter-individual variation in
the kindling-induced gene expression was observed in
the vehicle animals while the inter-individual variation,
as well as the absolute expression changes, was mark-
edly lower in the levetiracetam group indicating that
chronic application of 40 mg/kg levetiracetam had a
potent attenuating effect on the kindling-induced IEG
expression (Figure 5). Only one animal showed signifi-
cant differences in gene expression levels compared to
the rest of the levetiracetam-treated group; nevertheless,
animals expressing all kindling stages are represented in
the levetiracetam group.
In contrast, 80% of the fully kindled rats in the vehicle
group showed enhanced expression levels for all tested
genes whereas 50% of the stage 5 animals and only 43%
of the stage 3 animals exhibited enhanced expression
levels of the 8 examined genes. No inter-individual dif-
ferences in the relative expression levels of SV2A and
GAPDH were observed.
Rats with kindling-induced high IEG expression have
longer AD duration
In individual animals, we correlated the observed
changes in gene expression with kindling parameters
such as AD duration, seizure duration, seizure severity,
and stimulation number and stimulation amplitude.
Figure 3 Quantitative RT-PCR on total RNA from the contralateral hippocampus of individual control and amygdala-kindled rats of A.
Pcdh-8, B. COX-2, C. TIEG1 and D. GAPDH. The relative expression level of each cDNA was calculated by the ΔΔ-method, normalized to the
expression levels of b-actin in the sample. GAPDH was used as a control. The qPCR data is presented as mean ± SEM.
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Page 8 of 15However, no correlations at the single animal level were
found (data not shown). Based on the data presented in
Figure 5, which suggests that there are two discrete
populations of IEG responders, a one-way ANOVA was
performed on each of the individual gene data. The sta-
tistical analysis for 6 of the individual 8 genes consis-
tently identified 7 vehicle treated kindled animals as
having no significant differences in individual gene
expression compared to all the levetiracetam treated
kindled animals (except the outlier 5L2) (Tukey’sM u l t i -
ple Comparison Test, p > 0.05, n = 3). Vice versa, 9
vehicle treated kindled animals did have significant dif-
ferences in individual gene expression compared to all
levetiracetam animals (except the outlier 5L2) (Tukey’s
Multiple Comparison Test, p < 0.05, n = 3). These ani-
mals were categorized as “low IEG” and “high IEG”
expressing animals, respectively (see Figure 6 legend for
animal identifiers). Based on that analysis, we hypothe-
sized that kindling-induced gene expression in the hip-
pocampus is an “all-or-none response” that depends on
the progression of seizure activity from the amygdala to
the hippocampus. Indeed, “high IEG” expressing kindled
rats have an AD duration that is almost twice as long as
“low IEG” expressing kindled rats indicating that longer
AD duration times increase the likelihood of hippocam-
pal involvement in the seizure thereby giving rise to
increased gene expression (Figure 6). In support, the
only levetiracetam treated amygdala-kindled rat (5L2),
which exhibited “high IEG expression” also had a very
long AD duration time of 83 s. With respect to seizure
severity, seizure duration, stimulation number and sti-
mulation amplitude no statistically significant differences
were found between “high IEG” and “low IEG” kindled
rats (Figure 6).
Discussion
This study has 3 main findings. 1) Cox-2, TIEG1 and
Pcdh-8 are differentially expressed in the hippocampus
during the epileptic process in the kindled rat and the
differential expression is dependent on the duration of
Table 2 Effects of levetiracetam on kindling-induced IEG expression in the hippocampi of kindled rats
Ipsilateral Contralateral
Functional group mRNA Vehicle† Levetiracetam† % reduction % reduction
Egr3/Pilot 6.9 ± 0.4 2.4 ± 0.2 66 69
Transcription factors c-fos 5.8 ± 0.7 1.3 ± 0.1 77 67
Egr2/krox-20 12.5 ± 0.7 3.1 ± 0.2 75 88
NGF 1.4 ± 0.1 0.8 ± 0 45 9
Neurotrophic factors BDNF 7.4 ± 0.8 2.4 ± 0.1 67 70
NT-3 0.7 ± 0 0.9 ± 0.1 -22 -31
TGF-bb -A activin 13.1 ± 1.1 3 ± 0.1 77 89
superfamily TIEG1 6.2 ± 0.5 1.5 ± 0.1 76 72
Inflammatory TNF-a 4 ± 0.3 1.1 ± 0.1 74 54
response Cox-2 7.6 ± 0.5 2 ± 0.1 74 83
Homer-1a 10.6 ± 1 2.9 ± 0.2 73 77
GPCR interactions Ania-3 3.2 ± 0.2 2.5 ± 0.1 21 32
RGS-2 3.2 ± 0.1 0.8 ± 0.1 73 61
Extracellular MMP-9 6.7 ± 0.3 2.2 ± 0.2 67 59
proteins Narp 20.5 ± 1.8 2.5 ± 0.1 88 90
Cell adhesion Protocadherin-8 5.1 ± 0.3 1.1 ± 0.1 78 80
proteins Arc 15.9 ± 1.7 2.9 ± 0.1 82 78
Synaptopodin 2.1 ± 0.2 1.4 ± 0.1 33 38
Others Pim-1 kinase 4.3 ± 0.2 1.3 ± 0 70 71
GAPDH 1.2 ± 0.1 0.9 ± 0 22 14
† relative expression ± SEM to control start normalized to b-actin
Christensen et al. BMC Neuroscience 2010, 11:9
http://www.biomedcentral.com/1471-2202/11/9
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the amygdala. 2) All 3 genes belong to a seizure-induced
IEG expression profile that also comprises at least 16
other genes. Many of these genes have previously been
described in various models of synaptic plasticity. 3) In
o u rs t u d y ,w ea l s of o u n dt h at the anti-epileptic drug
levetiracetam attenuated the kindling-induced changes
of both immediate early and late response gene expres-
sion 3 hours after the last seizure. Previously, the effect
of levetiracetam on kindling-induced gene expression
after 1 hour has been reported for two single genes
BDNF and NPY [40] and after 24 hours for NPY, TRH
and GFAP [41] but never after 3 hours on a larger panel
of both IEG and late response genes. Consequently, our
data further expands the list of transcripts sensitive to
the actions of levetiracetam. In addition, we also found
that the attenuating effect of levetiracetam on seizure-
induced gene expression was paralleled by the drug
effect on AD duration which has not been reported pre-
viously. These findings suggest that levetiracetam during
epileptic seizures targets mechanisms that reduce the
AD duration which in turn prevents the increase in
mRNA expression of synaptic plasticity-related genes
in areas undergoing synaptic remodelling in response to
the enhanced neuronal activity which is reported to
occur both in vitro and in vivo [42,43].
Kindling-induced expression of a subset of genes
associated with synaptic remodeling
Utilising a DDRT-PCR based approach to find gene
expression changes in the hippocampus during amyg-
dala-kindling Cox-2 was identified as differentially
expressed. Cox-2 has previously been associated with
epileptic conditions in both animals and humans
[44,45]. Two additional kindling-induced transcripts
were identified and validated by the DDRT-PCR
method. Of these, TIEG1 was originally identified as dif-
ferentially expressed in human osteoblasts after TGF-b
activation [46]. It is induced in oligodendroglial precur-
sor cells after TGF-b treatment [47] and in rat brain
after kainate-induced seizures [48]. TGF-b is the most
potent inducer of TIEG1 but other members of the
TGF-b superfamily also induce TIEG1 including GDNF,
BMP-2 and b-A activin [49,50]. In contrast, information
on signaling cascades involving the cell-adhesion mole-
cule Pcdh-8 is very limited. Pcdh-8 is predominantly
expressed in the nervous system and during develop-
ment [51] and it has previously been implicated in neu-
ronal plasticity, long-term potentiation and synaptic
remodelling [52,53].
Subsequently, a bioinformatics approach combined
with quantitative RT-PCR lead to the identification of
16 additional kindling-induced genes. The differential
expressed transcripts fall into the following functional
categories: transcription factors (c-fos, krox-20 and
egr3), neurotrophic factors (NGF, BDNF and NT-3),
inflammatory response (Cox-2 and TNF-a), extracellu-
lar matrix components (Narp and MMP9), cell-adhe-
sion (Pcdh-8), TGF-b superfamily signaling (TIEG1
and b-A activin), GPCR signaling (RGS2, Homer1a and
Ania3) and others (Pim1 kinase, Arc and Synaptopo-
din). Historically, many of these transcripts have been
linked to synaptic plasticity and models of enhanced
neuronal activity [39,54-71,52,72,73]. In agreement,
DDRT-PCR studies in rapidly kindled mice revealed
differential expression of 26 transcripts amongst those
RGS2, krox-24, Homer and c-fos [74] and differential
expression of Cox-2, TIEG1, Narp, Arc, Ania-3,
Homer1a/Vesl and BDNF are also seen in the hippo-
campus after electroconvulsive shock [75]. Two of the
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Figure 4 Gene expression profiling the effects of levetiracetam on kindling-induced genes. Quantitative RT-PCR of RNA from the
contralateral hippocampus of levetiracetam and vehicle treated amygdala-kindled rats with primers against 8 seizure-induced genes and GAPDH
and SV2A as controls. All data are expressed relative to animal FL3, normalized to b-actin levels and expressed as mean ± SEM (n = 16). Asterisks
indicate a statistical significant difference in mean values between vehicle and levetiracetam groups. (p < 0.05, *; p < 0.01, **; Paired t-test).
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Figure 5 Single animal profiling the effects of levetiracetam on kindling-induced genes in amygdala-kindled rats. Quantitative RT-PCR of
RNA from the contralateral hippocampus of levetiracetam and vehicle treated amygdala-kindled rats with primers against 8 seizure-induced
genes and GAPDH and SV2A as control. Vehicle treated rats and levetiracetam treated animal pairs are numbered according to Table 1. In the
vehicle and the levetiracetam groups shaded, grey and black bars represent stage 3, stage 5 and fully kindled animals, respectively. White bars
represent lower than stage 3. All data are expressed relative to animal FL3, normalized to b-actin levels and expressed as mean ± SEM.
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Page 11 of 15differentially expressed transcripts Homer-1a and Ania-
3 originate from the same Homer 1 genetic loci [57].
However, we rule out a more general transcriptional
activation of the Homer 1 gene in amygdala-kindled
rats as a third splice variant of the Homer1 gene
Homer-1b/c is not differentially expressed after kind-
ling-induced seizures (see Additional file 1, Table S2).
Consequently, we propose that the kindling-induced
transcripts are molecular indicators of immediate early
changes, which are associated with enhanced neuronal
activity in the hippocampus in models of synaptic plas-
ticity including epilepsy models. Whether any, just a
subset or all of these genes are causal for the kindling
process still remains to be verified.
Induction of IEGs in the hippocampus seems to be an
“all-or-none” effect
The expression of c-fos mRNA has previously been
shown induced ipsilaterally after only a few ADs. How-
ever, upon repeated stimulations the kindling-induced c-
fos mRNA expression progresses to the contralateral
hippocampus in animals at stage 3 or more; at later
stages kindled animals exhibit no asymmetry in c-fos
expression [76]. Likewise, we also found a good correla-
tion between the ipsi- and contralateral hippocampus in
the normalized expression levels of Pcdh-8 and Cox-2
in stage 3 and stage 5 kindled rats. The progression of
mRNA expression of these genes from ipsilateral to
contralateral regions during progression of kindling at
earlier stages than stage 3 also indicates that these genes
are induced as a consequence of the spread of seizure
activity from ipsilateral to contralateral regions. Overall,
we observed no significant difference in the IEG mRNA
levels between stage 3, stage 5 and fully kindled popula-
tions. However, when analysing individual animals, a
higher frequency of IEG mRNA induction was seen at
the later stages compared to earlier kindling stages. This
could indicate an “all-or-none” effect in transcriptional
induction rather than a gradual increase in the tran-
scriptional response when animals progress from stage 3
to fully kindled. At the single animal level kindling-
induced IEG expression was observed in half of the
stage 5 and 80% of the fully kindled rats, respectively.
So even though the incident rate of IEG induction
increases with kindling acquisition not all kindled ani-
mals have changes in hippocampal IEG expression,
which is also in good agreement with previous studies
[76,77]. In addition, at the single animal level there
seems not to be a linear correlation between seizure
parameters like seizure severity and AD duration and
the relative mRNA expression levels of the examined
genes (Figure 5) suggesting an “all or none” effect of
kindling on IEG induction in the hippocampus. In sup-
port, kindled rats with “high IEG” expression also have
significant longer AD duration times than kindled rats
with “low IEG” expression.
Figure 6 Comparison of “High IEG” expressing (n = 9) and “Low IEG” expressing (n = 7) amygdala-kindled vehicle treated rats with
respect to A. AD duration, B. seizure severity, C. seizure duration, D. stimulation amplitude, and E. stimulation number. “High IEG” were
3V1, 3V7, 3V2, 5V3, 5V5, FV1, FV2, FV4 and FV3 whereas “Low IEG” animals were 5V2, FV5, 3V6, 3V5, 5V1, 3V4 and 3V3.All data are expressed as
mean ± SEM. Asterisks indicate a statistical significant difference in mean values between vehicle and levetiracetam groups. (p < 0.05, *;
Unpaired t-test and Mann-Whitney test).
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IEG transcripts involved in synaptic remodeling in the
hippocampus
In line with other studies we show that levetiracetam
exhibits an anti-epileptic effect in the amygdala-kindling
model, i.e. animals pre-treated with levetiracetam have
shorter AD duration and lower seizure severity com-
pared to non-treated controls [11,12]. In our study, the
anti-epileptic effect paralleled the observation that leve-
tiracetam also exerted a potent inhibitory effect on kind-
ling-induced changes in IEG mRNA expression in the
hippocampus. However, analysis of the individual ani-
mals revealed that only one of the 16 levetiracetam trea-
ted animals showed a significant change in the IEG
mRNA levels, whereas 9 of the 16 vehicle treated ani-
mals exhibited robust changes in IEG mRNA levels.
Nevertheless, 5 of 16 levetiracetam treated animals
developed stage 5 seizures during the treatment. No dif-
ference in the mRNA levels of the levetiracetam target
SV2A as well as in a number of other neuronal genes
was observed hence ruling out compensatory mechan-
isms as sensitization/desensitization of SV2A or even a
more general toxicity effect of the drug on neuronal
expressed mRNAs. Conclusively, this suggests that leve-
tiracetam might exert part of its anti-epileptic effect by
reducing the likelihood of an “all-or-none” induction of
genes putatively involved in establishing long term
synaptic changes important to kindling acquisition,
synaptic plasticity and perhaps epileptogenesis.
Expression of the IEG expression is not necessarily
induced during neuronal hypersynchronous seizure
activity in the hippocampus as it also requires bursts of
population spikes [77]. This has been further supported
by human studies showing correlation between spiking
activity and gene expression changes [78]. Levetiracetam
is able to inhibit hypersynchronous activity by reducing
the epileptiform activity-induced population spikes in
the CA3 area of the hippocampus [79-82]. This suggests
that levetiracetam is attenuating the kindling-induced
IEG mRNA expression by targeting mechanisms that
reduces the epileptiform activity-induced population
spikes in the hippocampus. However, it would require a
recording electrode in the hippocampus to be able to
correlate the AD duration time, existence of population
spike activity in the hippocampus and increased IEG
expression to the attenuating effects of levetiracetam.
Conclusions
In conclusion, our data suggest that levetiracetam is a
potent inhibitor of the immediate early transcriptional
responses to episodes of enhanced neuronal spiking
activity in the hippocampus. Given that many of these
transcripts are encoding proteins involved in synaptic
remodeling also suggests that levetiracetam could inhibit
structural changes in areas undergoing synaptic plasticity.
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